Coya Therapeutics Inc COYA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
-
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease
-
Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase
-
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
-
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
-
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Trading Information
- Previous Close Price
- $5.36
- Day Range
- $5.26–5.52
- 52-Week Range
- $3.71–7.75
- Bid/Ask
- $5.30 / $6.05
- Shares Outstanding
- 23.46M
- Market Cap
- $123.38M
- Volume/Avg
- 264,280 / 184,709
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 13.19
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 8
- Website
- https://www.coyatherapeutics.com
Valuation
|
Metric
|
COYA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.75 |
Price/Sales | 13.19 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
COYA
|
|---|---|
Quick Ratio | 14.30 |
Current Ratio | 15.02 |
Interest Coverage | — |
Quick Ratio
COYA
Profitability
|
Metric
|
COYA
|
|---|---|
Return on Assets (Normalized) | −37.95% |
Return on Equity (Normalized) | −43.44% |
Return on Invested Capital (Normalized) | −43.44% |
Return on Assets
COYA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^z?Y<#l | LOCK|mc@s | $126B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|wW^zH<# | LOCK|Y#<$ | $70B | |||
| argenx SE ADR
ARGX
| LOCK|H^Dy@vB | LOCK|#y! | $57B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#L>hPqM | LOCK|&xqKN | $42B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Gn$fC& | LOCK|p$ | $35B | |||
| Moderna Inc
MRNA
| LOCK|<!CJ%!b | LOCK|Sj | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!^$%R?<k | LOCK|yr&? | $26B | |||
| Incyte Corp
INCY
| LOCK|#$jj$ND | LOCK|!j | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|vhT>&$$ | LOCK|yg@ | $24B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|xdbTX?S | LOCK|t& | $18B |
United States